SCHEMBL22196893

SCHEMBL22196893

N#C/C(=C\c1ccc(-c2ccccc2Cl)o1)C(N)=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.67
GAA P10253 4/20 0.67
MEN1 O00255 4/20 0.67
ALDH1A1 P00352 4/20 0.67
POLB P06746 3/20 0.67
MAPT P10636 9/20 0.64
TP53 P04637 3/20 0.64
MCL1 Q07820 2/20 0.58
SIRT2 Q8IXJ6 1/20 0.56
LMNA P02545 4/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
ALOX12 P18054 1/20 0.54
BLM P54132 1/20 0.51
USP2 O75604 1/20 0.48
IDE P14735 1/20 0.48
GPR35 Q9HC97 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819017 0.88 MAPT (0.65) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL2819014 0.88 MAPT (0.65) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL2137995 0.81 MAPT (0.79) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL14472235 0.81 MAPT (0.79) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL18084859 0.79 MEN1 (0.64) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL38659067 0.73 MAPT (0.66) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL38659253 0.72 MAPT (0.77) KMT2AGAAMEN1POLBMAPT
SCHEMBL7821288 0.71 PTPN1 (0.52) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL7821289 0.71 PTPN1 (0.52) KMT2AGAAMEN1ALDH1A1POLB
SCHEMBL1616299 0.71 KDM4E (0.58) KMT2AGAAMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2022-09-22 US disclosed
US-20210002337-A1 IN VIVO ENGINEERED CEREBLON PROTEIN THE SCRIPPS RESEARCH INSTITUTE 2021-01-07 US disclosed
US-10781239-B2 In vivo engineered cereblon protein VIVIDION THERAPEUTICS, INC. (US) 2020-09-22 US disclosed
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2020-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885GAA 4676/4885MEN1 425/4885
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885GAA 4676/4885MEN1 425/4885
US-20210002337-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 KMT2A 607/4885GAA 4676/4885MEN1 425/4885
US-10781239-B2 In vivo engineered cereblon protein CRBN, CDR2, DCUN1D4 KMT2A 607/4885GAA 4676/4885MEN1 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.